Business Description
Brainstorm Cell Therapeutics Inc
NAICS : 325412
SIC : 2836
ISIN : US10501E2019
Description
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.2 | |||||
| Equity-to-Asset | -2.99 | |||||
| Debt-to-Equity | -0.14 | |||||
| Debt-to-EBITDA | -0.06 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 22.5 | |||||
| 3-Year EPS without NRI Growth Rate | 21.9 | |||||
| 3-Year FCF Growth Rate | 26.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 44.89 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.87 | |||||
| 9-Day RSI | 29.9 | |||||
| 14-Day RSI | 35.42 | |||||
| 3-1 Month Momentum % | 4.6 | |||||
| 6-1 Month Momentum % | -60.73 | |||||
| 12-1 Month Momentum % | -66.94 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.05 | |||||
| Quick Ratio | 0.05 | |||||
| Cash Ratio | 0.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -19.8 | |||||
| Shareholder Yield % | -85.72 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -339.64 | |||||
| ROIC % | -337.2 | |||||
| 3-Year ROIIC % | -151.62 | |||||
| ROC (Joel Greenblatt) % | -592.15 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -0.74 | |||||
| EV-to-Forward-EBIT | -0.56 | |||||
| EV-to-EBITDA | -0.75 | |||||
| EV-to-Forward-EBITDA | -0.58 | |||||
| EV-to-FCF | -0.86 | |||||
| Earnings Yield (Greenblatt) % | -135.14 | |||||
| FCF Yield % | -123.3 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:BCLI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Brainstorm Cell Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.51 | ||
| Beta | 0.84 | ||
| 3-Year Sharpe Ratio | -0.22 | ||
| 3-Year Sortino Ratio | -0.31 | ||
| Volatility % | 103.01 | ||
| 14-Day RSI | 35.42 | ||
| 14-Day ATR ($) | 0.136408 | ||
| 20-Day SMA ($) | 1.7649 | ||
| 12-1 Month Momentum % | -66.94 | ||
| 52-Week Range ($) | 1.05 - 11.890499 | ||
| Shares Outstanding (Mil) | 5.7 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Brainstorm Cell Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Brainstorm Cell Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Brainstorm Cell Therapeutics Inc Frequently Asked Questions
What is Brainstorm Cell Therapeutics Inc(BCLI)'s stock price today?
The current price of BCLI is $1.61. The 52 week high of BCLI is $11.89 and 52 week low is $1.05.
When is next earnings date of Brainstorm Cell Therapeutics Inc(BCLI)?
The next earnings date of Brainstorm Cell Therapeutics Inc(BCLI) is 2025-04-01 Est..
Does Brainstorm Cell Therapeutics Inc(BCLI) pay dividends? If so, how much?
Brainstorm Cell Therapeutics Inc(BCLI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers